Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:1612
Name breast cancer
Definition A thoracic cancer that originates in the mammary gland.
Source DiseaseOntology.org
Alt Ids DOID:4241 DOID:1648
Path disease disease of cellular proliferation cancer organ system cancer thoracic cancer breast cancer

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA mutant VS-5584 breast cancer sensitive detail...
TP53 P72R Daunorubicin breast cancer predicted - sensitive detail...
TP53 P72R Daunoxome breast cancer predicted - sensitive detail...
TP53 P72R Pegylated liposomal-doxorubicin breast cancer predicted - sensitive detail...
TP53 P72R Epirubicin breast cancer sensitive detail...
PIK3CA mutant Sapanisertib breast cancer sensitive detail...
PIK3CA act mut Copanlisib breast cancer sensitive detail...
TP53 P72R TP53 Y220C Cyclophosphamide + Epirubicin breast cancer no benefit detail...
ATM dec exp Talazoparib breast cancer sensitive detail...
TP53 inact mut Adavosertib + Radiotherapy breast cancer sensitive detail...
TP53 negative Bevacizumab + Docetaxel + Doxorubicin breast cancer sensitive detail...
TP53 inact mut AMG 900 breast cancer sensitive detail...
PIK3CA E545K Everolimus breast cancer sensitive detail...
PIK3CA act mut MK2206 breast cancer sensitive detail...
RAD51B wild-type N/A breast cancer not applicable detail...
FGFR2 amp Dovitinib breast cancer sensitive detail...
FBXW7 inact mut Sirolimus breast cancer sensitive detail...
PTEN mutant Sapanisertib breast cancer sensitive detail...
CDKN2A mut PIK3CA mut Sapanisertib breast cancer sensitive detail...
PIK3CA mutant Capivasertib breast cancer predicted - sensitive detail...
PIK3CA mutant Pictilisib breast cancer sensitive detail...
PIK3CA mutant Temsirolimus breast cancer no benefit detail...
ATR positive VE-821 breast cancer predicted - sensitive detail...
FGFR2 over exp AZ8010 breast cancer sensitive detail...
FGFR2 over exp AZD4547 breast cancer sensitive detail...
PIK3CA P539R PIK3CA H1047R PF-04691502 breast cancer sensitive detail...
PIK3CA mutant AZD8835 breast cancer sensitive detail...
PIK3CA E545K WYE-125132 breast cancer sensitive detail...
PIK3CA mutant CH5132799 breast cancer sensitive detail...
PIK3CA H1047R CH5132799 breast cancer sensitive detail...
PIK3CA E545K CH5132799 breast cancer sensitive detail...
PIK3CA E542K CH5132799 breast cancer sensitive detail...
PIK3CA mutant CUDC-907 breast cancer sensitive detail...
PTEN A72fs Gedatolisib breast cancer sensitive detail...
PIK3CA H1047R Gedatolisib breast cancer sensitive detail...
PIK3CA E545K Gedatolisib breast cancer sensitive detail...
FGFR2 over exp PD173074 breast cancer sensitive detail...
FGFR1 amp Ponatinib breast cancer sensitive detail...
FGFR2 amp Ponatinib breast cancer sensitive detail...
FGFR2 wild-type Ponatinib breast cancer resistant detail...
FGFR1 wild-type Ponatinib breast cancer resistant detail...
FGFR1 act mut FIIN-1 breast cancer sensitive detail...
FGFR2 amp Debio 1347 breast cancer sensitive detail...
PIK3CA E542K Dactolisib breast cancer sensitive detail...
PIK3CA E545K Dactolisib breast cancer sensitive detail...
PIK3CA G1049R Dactolisib breast cancer sensitive detail...
PIK3CA H1047L Dactolisib breast cancer sensitive detail...
PIK3CA H1047R Dactolisib breast cancer sensitive detail...
PIK3CA N345K Dactolisib breast cancer sensitive detail...
PIK3CA Q546K Dactolisib breast cancer sensitive detail...
PIK3CA E542K Alpelisib breast cancer sensitive detail...
PIK3CA E545K Alpelisib breast cancer sensitive detail...
PIK3CA G1049R Alpelisib breast cancer sensitive detail...
PIK3CA H1047L Alpelisib breast cancer sensitive detail...
PIK3CA H1047R Alpelisib breast cancer sensitive detail...
PIK3CA N345K Alpelisib breast cancer sensitive detail...
PIK3CA Q546K Alpelisib breast cancer sensitive detail...
PIK3CA E542K MK2206 breast cancer sensitive detail...
PIK3CA E545K MK2206 breast cancer sensitive detail...
PIK3CA G1049R MK2206 breast cancer sensitive detail...
PIK3CA H1047L MK2206 breast cancer sensitive detail...
PIK3CA H1047R MK2206 breast cancer sensitive detail...
PIK3CA N345K MK2206 breast cancer sensitive detail...
PIK3CA Q546K MK2206 breast cancer sensitive detail...
PIK3CA E542K Lapatinib breast cancer sensitive detail...
PIK3CA E545K Lapatinib breast cancer sensitive detail...
PIK3CA G1049R Lapatinib breast cancer sensitive detail...
PIK3CA H1047L Lapatinib breast cancer sensitive detail...
PIK3CA H1047R Lapatinib breast cancer sensitive detail...
PIK3CA N345K Lapatinib breast cancer sensitive detail...
PIK3CA Q546K Lapatinib breast cancer sensitive detail...
PIK3CA E542K Neratinib breast cancer sensitive detail...
PIK3CA E545K Neratinib breast cancer sensitive detail...
PIK3CA G1049R Neratinib breast cancer sensitive detail...
PIK3CA H1047L Neratinib breast cancer sensitive detail...
PIK3CA H1047R Neratinib breast cancer sensitive detail...
PIK3CA N345K Neratinib breast cancer sensitive detail...
PIK3CA Q546K Neratinib breast cancer sensitive detail...
PIK3CA E542K Trametinib breast cancer sensitive detail...
PIK3CA E545K Trametinib breast cancer sensitive detail...
PIK3CA G1049R Trametinib breast cancer sensitive detail...
PIK3CA H1047L Trametinib breast cancer sensitive detail...
PIK3CA H1047R Trametinib breast cancer sensitive detail...
PIK3CA N345K Trametinib breast cancer sensitive detail...
PIK3CA Q546K Trametinib breast cancer sensitive detail...
PIK3CA act mut MK2206 + Ridaforolimus breast cancer predicted - sensitive detail...
PTEN loss AZD6482 breast cancer sensitive detail...
PTEN loss GSK2636771 breast cancer sensitive detail...
PIK3CA mut PTEN loss Alpelisib breast cancer resistant detail...
PIK3CA mut PTEN loss Buparlisib breast cancer sensitive detail...
PIK3CA mut PTEN loss Alpelisib + AZD6482 breast cancer sensitive detail...
TP53 L194F Tanespimycin + Vorinostat breast cancer sensitive detail...
TP53 L194F Tanespimycin breast cancer sensitive detail...
TP53 L194F Vorinostat breast cancer sensitive detail...
TP53 R280K Ganetespib breast cancer sensitive detail...
TP53 L194F Ganetespib breast cancer sensitive detail...
TP53 R175H Ganetespib breast cancer sensitive detail...
PIK3CA wild-type PTEN loss AZD8835 breast cancer resistant detail...
ALK wild-type Cisplatin + Dalantercept breast cancer predicted - sensitive detail...
PIK3CA E545K PKI-402 breast cancer sensitive detail...
RET positive Y078-DM4 breast cancer sensitive detail...
RET over exp Y078-DM1 breast cancer sensitive detail...
PIK3CA mutant GSK2126458 breast cancer no benefit detail...
PIK3CA mutant Letrozole + Taselisib breast cancer sensitive detail...
PIK3CA mutant Alpelisib + GSK2334470 breast cancer sensitive detail...
FGFR1 amp AZD4547 breast cancer no benefit detail...
TP53 wild-type KRT-232 breast cancer sensitive detail...
TP53 wild-type KRT-232 + Radiotherapy breast cancer sensitive detail...
FGFR2 fusion FGFR2 amp PRN1371 breast cancer sensitive detail...
PTEN mutant MS417 + Pictilisib breast cancer predicted - sensitive detail...
PIK3CA mutant OSI-027 breast cancer sensitive detail...
PTEN loss OSI-027 breast cancer sensitive detail...
PIK3CA K111N BAY1125976 breast cancer sensitive detail...
PIK3CA H1047R BAY1125976 breast cancer sensitive detail...
PIK3CA E545K BAY1125976 breast cancer sensitive detail...
PTEN L108R BAY1125976 breast cancer sensitive detail...
PTEN T319fs BAY1125976 breast cancer sensitive detail...
PIK3CA H1047R PTEN E307K BAY1125976 breast cancer sensitive detail...
PIK3CA P539R BAY1125976 breast cancer sensitive detail...
PTEN C136Y Alpelisib breast cancer resistant detail...
PTEN loss Alpelisib breast cancer resistant detail...
FGFR2 positive Aprutumab ixadotin breast cancer sensitive detail...
FGFR2 dec exp Aprutumab ixadotin breast cancer resistant detail...
FGFR2 amp AZD4547 breast cancer sensitive detail...
FGFR1 amp FGFR2 amp E7090 breast cancer sensitive detail...
PIK3CA H1047R Metformin breast cancer sensitive detail...
TP53 wild-type SAR405838 breast cancer predicted - sensitive detail...
FGFR1 amp Infigratinib breast cancer sensitive detail...
FGFR2 amp Infigratinib breast cancer predicted - sensitive detail...
PTEN mutant CUDC-907 breast cancer sensitive detail...
PTEN del CUDC-907 breast cancer sensitive detail...
PIK3CA act mut Dactolisib + Venetoclax breast cancer no benefit detail...
PIK3CA H1047R PTEN loss Dactolisib + Venetoclax breast cancer no benefit detail...
PIK3CA E545K Dactolisib + Venetoclax breast cancer no benefit detail...
PIK3CA act mut Dactolisib + WEHI-539 breast cancer predicted - sensitive detail...
PIK3CA H1047R PTEN loss Dactolisib + WEHI-539 breast cancer predicted - sensitive detail...
PIK3CA E545K Dactolisib + WEHI-539 breast cancer predicted - sensitive detail...
PIK3CA E542K PTEN loss Dactolisib + WEHI-539 breast cancer predicted - sensitive detail...
PIK3CA wild-type Dactolisib + WEHI-539 breast cancer no benefit detail...
PIK3CA act mut Buparlisib + WEHI-539 breast cancer no benefit detail...
PIK3CA act mut Alpelisib + WEHI-539 breast cancer no benefit detail...
PIK3CA act mut Torin 1 + WEHI-539 breast cancer predicted - sensitive detail...
PIK3CA act mut Sapanisertib + WEHI-539 breast cancer predicted - sensitive detail...
PIK3CA act mut Vistusertib + WEHI-539 breast cancer predicted - sensitive detail...
PIK3CA wild-type A-1210477 + WEHI-539 breast cancer predicted - sensitive detail...
PIK3CA H1047R Miransertib breast cancer sensitive detail...
PIK3CA H1047R ARQ 751 breast cancer sensitive detail...
PIK3CA E545K Miransertib breast cancer sensitive detail...
PIK3CA K111N Miransertib breast cancer sensitive detail...
PIK3CA P539R PIK3CA H1047R Miransertib breast cancer sensitive detail...
PIK3CA E545K ARQ 751 breast cancer sensitive detail...
PIK3CA K111N ARQ 751 breast cancer sensitive detail...
PIK3CA P539R PIK3CA H1047R ARQ 751 breast cancer sensitive detail...
PIK3CA E542K Miransertib breast cancer sensitive detail...
PIK3CA H1047R M2698 breast cancer sensitive detail...
PIK3CA E545K DHM25 breast cancer sensitive detail...
PIK3CA H1047R DHM25 breast cancer sensitive detail...
PTEN L108R DHM25 breast cancer sensitive detail...
PIK3CA K111N DHM25 breast cancer sensitive detail...
PIK3CA act mut PTEN wild-type Everolimus breast cancer sensitive detail...
PIK3CA act mut PTEN wild-type Torkinib breast cancer sensitive detail...
PTEN loss Everolimus breast cancer resistant detail...
PTEN loss Torkinib breast cancer resistant detail...
PIK3CA wild-type PTEN loss Everolimus + U0126 breast cancer no benefit detail...
PIK3CA wild-type PTEN loss Everolimus + Selumetinib breast cancer no benefit detail...
PIK3CA wild-type PTEN loss Torkinib + U0126 breast cancer sensitive detail...
PIK3CA wild-type PTEN loss Selumetinib + Torkinib breast cancer sensitive detail...
PIK3CA E545K Voxtalisib breast cancer sensitive detail...
TP53 R175H NSC319726 breast cancer sensitive detail...
TP53 R273W NSC319726 breast cancer resistant detail...
TP53 positive Serdemetan breast cancer sensitive detail...
PIK3CA mutant AT13148 breast cancer sensitive detail...
TP53 mutant PK11007 breast cancer sensitive detail...
PIK3CA H1047R Taselisib breast cancer sensitive detail...
PIK3CA H1047R Buparlisib breast cancer sensitive detail...
PIK3CA mutant MLN1117 breast cancer predicted - sensitive detail...
FGFR2 positive Rogaratinib breast cancer predicted - sensitive detail...
HRAS mutant PI-273 breast cancer decreased response detail...
PIK3CA mutant GDC-0077 breast cancer predicted - sensitive detail...
FGFR2 - GAB2 FGFR2 amp PRN1371 breast cancer sensitive detail...
PIK3CA H450_P458del Alpelisib breast cancer sensitive detail...
FGFR2 amp Derazantinib breast cancer sensitive detail...
PIK3CA E39K Buparlisib breast cancer resistant detail...
PIK3CA N345I Buparlisib breast cancer resistant detail...
PIK3CA E453K Buparlisib breast cancer resistant detail...
PIK3CA E542K Buparlisib breast cancer resistant detail...
PIK3CA E545K Buparlisib breast cancer resistant detail...
PIK3CA G1049R Buparlisib breast cancer resistant detail...
KIT positive Imatinib + Letrozole breast cancer predicted - sensitive detail...
BRAF L514V Dabrafenib breast cancer resistant detail...
RB1 positive Paclitaxel + Palbociclib breast cancer predicted - sensitive detail...
PIK3CA mutant MK2206 breast cancer no benefit detail...
PTEN loss MK2206 breast cancer no benefit detail...
FGFR2 - GAB2 Infigratinib breast cancer predicted - sensitive detail...
PIK3CA H1047R CYH33 breast cancer sensitive detail...
PIK3CA mutant CYH33 breast cancer predicted - sensitive detail...
PTEN loss CYH33 breast cancer no benefit detail...
PIK3CA P539R CYH33 breast cancer predicted - sensitive detail...
PIK3CA H1047R PTEN loss CYH33 breast cancer predicted - sensitive detail...
PIK3CA E542K PTEN loss CYH33 breast cancer predicted - sensitive detail...
PIK3CA E545K CYH33 breast cancer predicted - sensitive detail...
BRAF E451K Dabrafenib breast cancer predicted - resistant detail...
BRAF T599K Dabrafenib breast cancer predicted - resistant detail...
BRAF G596D Dabrafenib breast cancer predicted - resistant detail...
BRAF T310I Dabrafenib breast cancer predicted - resistant detail...
PTEN L108R Borussertib breast cancer sensitive detail...
PTEN L108R Miransertib breast cancer sensitive detail...
PTEN L108R Capivasertib breast cancer sensitive detail...
PTEN L108R MK2206 breast cancer sensitive detail...
PTEN L108R Ipatasertib breast cancer sensitive detail...
PIK3CA K111N Borussertib breast cancer sensitive detail...
PIK3CA E545K Borussertib breast cancer sensitive detail...
PIK3CA H1047R Borussertib breast cancer sensitive detail...
PIK3CA E545K PIK3CA E726K Alpelisib breast cancer sensitive detail...
PIK3CA E545K PIK3CA M1043L Alpelisib breast cancer sensitive detail...
PIK3CA E453Q PIK3CA H1047R Alpelisib breast cancer sensitive detail...
PIK3CA E726K PIK3CA H1047R Alpelisib breast cancer sensitive detail...
PIK3CA E545K PIK3CA E726K GDC-0077 breast cancer sensitive detail...
PIK3CA E545K PIK3CA M1043L GDC-0077 breast cancer sensitive detail...
PIK3CA E453Q PIK3CA H1047R GDC-0077 breast cancer sensitive detail...
PIK3CA E726K PIK3CA H1047R GDC-0077 breast cancer sensitive detail...
PIK3CA E545K PIK3CA E726K Everolimus breast cancer sensitive detail...
PIK3CA E545K PIK3CA M1043L Everolimus breast cancer sensitive detail...
PIK3CA E453Q PIK3CA H1047R Everolimus breast cancer sensitive detail...
PIK3CA E726K PIK3CA H1047R Everolimus breast cancer sensitive detail...
PTEN loss Palbociclib breast cancer decreased response detail...
PTEN loss Ribociclib breast cancer predicted - resistant detail...
PTEN loss Fulvestrant + Ribociclib breast cancer resistant detail...
PTEN loss MK2206 + Ribociclib breast cancer sensitive detail...
PTEN loss Ipatasertib + Ribociclib breast cancer sensitive detail...
PTEN loss MK2206 + Palbociclib breast cancer sensitive detail...
PTEN loss Ipatasertib + Palbociclib breast cancer sensitive detail...
PTEN loss Fulvestrant + MK2206 + Ribociclib breast cancer sensitive detail...
EML4 - ALK Ceritinib breast cancer sensitive detail...
EML4 - ALK Fulvestrant breast cancer resistant detail...
EML4 - ALK Ceritinib + Fulvestrant breast cancer predicted - sensitive detail...
PIK3CA E545K Ipatasertib breast cancer sensitive detail...
PIK3CA E545K Ipatasertib + Paclitaxel breast cancer sensitive detail...
FGFR2 amp Futibatinib breast cancer predicted - sensitive detail...
PIK3CA D939G Gedatolisib breast cancer sensitive detail...
PIK3CA E542K PTEN loss Taselisib breast cancer sensitive detail...
PIK3CA H1047R PTEN loss Taselisib breast cancer sensitive detail...
PTEN Y336* Veliparib breast cancer sensitive detail...
FGFR1 amp FGFR2 amp Regorafenib breast cancer sensitive detail...
PIK3CA H1047R TAS-117 breast cancer predicted - sensitive detail...
RB1 negative SHR6390 breast cancer no benefit detail...
MSH6 negative Dostarlimab-gxly breast cancer sensitive detail...
MLH1 negative Dostarlimab-gxly breast cancer sensitive detail...
FGFR1 amp FGFR2 amp Futibatinib breast cancer sensitive detail...
FGFR1 amp Futibatinib breast cancer predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00194714 Phase Ib/II HER2 Vaccine Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab Active, not recruiting USA 0
NCT00313599 Phase I Lapatinib + Paclitaxel Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors Completed USA 0
NCT00378638 Phase II Bevacizumab Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer Unknown status USA 0
NCT00570323 Phase II Anastrozole + Fulvestrant Anastrozole Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer Completed USA 0
NCT00618657 Phase II Carboplatin + Nab-paclitaxel + Trastuzumab Bevacizumab + Carboplatin + Nab-paclitaxel Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting Active, not recruiting USA 0
NCT00651976 Phase I Letrozole Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery Terminated USA 0
NCT00719875 Phase Ib/II Vorinostat HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer Completed USA 0
NCT00733408 Phase II Bevacizumab + Erlotinib + Nab-paclitaxel Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer Completed USA 0
NCT00740805 Phase I Aldoxorubicin + Cyclophosphamide + Veliparib Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT00892736 Phase I Veliparib Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy Completed USA 0
NCT00912340 Phase II Everolimus Trastuzumab Randomized Phase II Trial of Trastuzumab or EVEROLIMUS in Hormone-refractory Metastatic Breast Cancer Completed USA 0
NCT00968968 Phase III Trastuzumab Lapatinib + Trastuzumab Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone Terminated USA | CAN 0
NCT00978250 Phase II 5-Fluoro-2-deoxycytidine + Tetrahydrouridine A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) Completed USA 0
NCT01008150 Phase II Cyclophosphamide + Doxorubicin + Neratinib + Paclitaxel + Trastuzumab Cyclophosphamide + Doxorubicin + Paclitaxel + Trastuzumab Cyclophosphamide + Doxorubicin + Neratinib + Paclitaxel Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer Completed USA | CAN 3
NCT01035099 Phase I Letrozole RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF Active, not recruiting USA 0
NCT01037790 Phase II Palbociclib PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER Completed USA 0
NCT01042379 Phase II Trebananib Pertuzumab + Trastuzumab Ganitumab Cyclophosphamide + Doxorubicin + Paclitaxel MK2206 + Trastuzumab Trastuzumab + Trebananib Ado-trastuzumab emtansine + Pertuzumab I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Recruiting USA 0
NCT01042535 Phase Ib/II Ad.p53-DC vaccine + Indoximod Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer Completed USA 0
NCT01097278 Phase 0 Cholecalciferol S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer Completed USA 0
NCT01106898 Phase II Cyclophosphamide + Paclitaxel Trastuzumab Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Treating Women With Stage I or Stage II Breast Cancer Who Have Undergone Surgery Completed USA 0
NCT01148849 Phase I Margetuximab-cmkb Safety Study of MGAH22 in HER2-positive Carcinomas Active, not recruiting USA 1
NCT01194869 Phase II Cisplatin + Paclitaxel + Sorafenib Preoperative Clinical Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Triple Negative (ER-, PR-, Her2-)Early Stage Breast Cancer Terminated USA 0
NCT01216176 Phase Ib/II Anastrozole Saracatinib A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZDO530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer Completed USA 0
NCT01262027 Phase II Dovitinib TKI258 for Metastatic Inflammatory Breast Cancer Patients Completed USA 0
NCT01275677 Phase III Cyclophosphamide + Doxorubicin + Paclitaxel + Trastuzumab Cyclophosphamide + Docetaxel Cyclophosphamide + Docetaxel + Trastuzumab Cyclophosphamide + Doxorubicin + Paclitaxel Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Active, not recruiting USA | CAN 2
NCT01281150 Phase I Veliparib Paclitaxel Carboplatin Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors Completed USA 0
NCT01283789 Phase II Everolimus + Lapatinib Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer Unknown status USA 0
NCT01286987 Phase I Talazoparib Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors Completed USA 1
NCT01293032 Phase I Tamoxifen Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer Completed USA | CAN 0
NCT01300962 Phase I Buparlisib + Capecitabine + Lapatinib Buparlisib + Capecitabine + Trastuzumab Buparlisib + Capecitabine Alpelisib + Capecitabine Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer Completed USA 0
NCT01302379 Phase I Metformin Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors Completed USA 0
NCT01310231 Phase II Metformin A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer Completed CAN 0
NCT01320592 Phase I Palbociclib Paclitaxel PD0332991/Paclitaxel in Advanced Breast Cancer Completed USA 0
NCT01325441 Phase Ib/II Napabucasin + Paclitaxel A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Completed USA | CAN 0
NCT01340300 Phase II Metformin Exercise and Metformin in Colorectal and Breast Cancer Survivors Completed USA 0
NCT01366144 Phase I Paclitaxel Veliparib Carboplatin Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Active, not recruiting USA 0
NCT01384253 Phase I 212Pb-TCMC-Trastuzumab + Trastuzumab Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy Completed USA 0
NCT01386580 Phase Ib/II 2B3-101 2B3-101 + Trastuzumab An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. Completed USA 3
NCT01401959 Phase II Eribulin Eribulin + Trastuzumab Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy Completed USA 0
NCT01407562 Phase I Carboplatin Paclitaxel Pazopanib Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors Active, not recruiting USA 0
NCT01480583 Phase II Trastuzumab GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases Completed USA 0
NCT01501487 FDA approved Cyclophosphamide + Docetaxel + Doxorubicin Cyclophosphamide + Epirubicin + Fluorouracil Paclitaxel Pegfilgrastim Cyclophosphamide + Docetaxel Cyclophosphamide + Doxorubicin Carboplatin + Docetaxel + Trastuzumab Docetaxel + Pertuzumab + Trastuzumab MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I Completed USA 0
NCT01506609 Phase II Temozolomide + Veliparib Carboplatin + Etoposide + Veliparib Carboplatin + Paclitaxel The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer Completed USA | CAN 18
NCT01517802 Phase III Abiraterone A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate Completed USA 6
NCT01525589 Phase II Lurbinectedin A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer Completed USA 1
NCT01532960 Phase I Poly ICLC Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer (Breast 41) Terminated USA 0
NCT01545648 Phase II Denosumab Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer Terminated USA 0
NCT01562873 Phase II Ruxolitinib Ruxolitinib in Patients With Breast Cancer Terminated USA 0
NCT01570036 Phase II E75 Sargramostim Trastuzumab Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax Completed USA 0
NCT01576666 Phase Ib/II Buparlisib + Sonidegib Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors Completed USA | CAN 6
NCT01596751 Phase Ib/II Eribulin Pexidartinib Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer Completed USA 0
NCT01597388 Phase I Fulvestrant + Vistusertib AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer Active, not recruiting USA 0
NCT01618357 Phase I Veliparib Pre-Operative Radiation and Veliparib for Breast Cancer Recruiting USA 0
NCT01625286 Phase Ib/II Capivasertib + Paclitaxel Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients Active, not recruiting CAN 10
NCT01640665 Phase I Capecitabine + Sorafenib Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors Completed USA 0
NCT01650506 Phase I Erlotinib + Metformin Study of Erlotinib and Metformin in Triple Negative Breast Cancer Completed USA 0
NCT01656538 Phase II Pelareorep Paclitaxel A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer Completed CAN 0
NCT01669343 Phase I Letrozole Aromatase Inhibitor Host Factors Study Completed CAN 0
NCT01676753 Phase I Dinaciclib + Pembrolizumab Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer Active, not recruiting USA 0
NCT01723774 Phase II Palbociclib Anastrozole Goserelin PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer Active, not recruiting USA 0
NCT01730833 Phase II Paclitaxel + Pertuzumab + Trastuzumab Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer Active, not recruiting USA 0
NCT01750073 Phase II Doxorubicin Trastuzumab Cyclophosphamide + Paclitaxel Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Stage I-III Breast Cancer Active, not recruiting USA 0
NCT01831089 Phase I Bevacizumab + Lurbinectedin + Paclitaxel Lurbinectedin + Paclitaxel Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors Completed USA 2
NCT01837602 Phase I cMet CAR RNA T Cells Targeting Breast Cancer Completed USA 0
NCT01847001 Phase II Propranolol Paclitaxel + Pertuzumab + Trastuzumab Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy Completed USA 0
NCT01853306 Phase I Veliparib A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors Completed 0
NCT01862900 Phase Ib/II MEDI6469 Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions Completed USA 0
NCT01868503 Phase II Lapatinib Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer Terminated USA 0
NCT01870505 Phase I Alpelisib + Exemestane Alpelisib + Letrozole BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer Active, not recruiting USA 0
NCT01876251 Phase I Docetaxel + Nirogacestat A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer Terminated USA 3
NCT01920061 Phase I Dacomitinib + Gedatolisib Cisplatin + Gedatolisib Docetaxel + Gedatolisib A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) Completed USA | CAN 3
NCT01934335 Phase I Vandetanib Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer Terminated USA 0
NCT01966445 Phase I GSK2849330 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors Completed USA 2
NCT01980823 Phase I Atorvastatin + Metformin Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer Recruiting USA 0
NCT01989546 Phase Ib/II Talazoparib Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations Completed USA 0
NCT01990209 Phase II Orteronel Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) Completed USA 0
NCT01990352 Phase II Pegylated liposomal-doxorubicin Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy Active, not recruiting USA 0
NCT02000622 Phase III Olaparib Vinorelbine Eribulin Capecitabine Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD) Active, not recruiting USA 18
NCT02007512 Phase II Enzalutamide + Exemestane Exemestane Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer Active, not recruiting USA | CAN 5
NCT02014337 Phase I Eribulin + Mifepristone Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Completed USA 0
NCT02025803 Phase I Capecitabine + TAS-114 A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors Completed USA 0
NCT02040857 Phase II Exemestane Palbociclib Tamoxifen Letrozole Anastrozole A Study of Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer Completed USA 0
NCT02041429 Phase Ib/II Paclitaxel + Ruxolitinib Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca Completed USA 0
NCT02046421 Phase I Mifepristone Carboplatin + Gemcitabine Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Completed USA 0
NCT02047747 Phase II Dacomitinib A Phase II Study of Dacomitinib in Progressive Brain Metastases Terminated USA 0
NCT02048059 Phase II Paclitaxel Trevatide ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases Completed USA 0
NCT02051751 Phase I Alpelisib + Paclitaxel A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer Completed USA 3
NCT02077933 Phase I Alpelisib + Everolimus Alpelisib + Everolimus + Exemestane Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors Completed USA 8
NCT02122861 Phase I ID-LV305 A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 Completed USA 0
NCT02124148 Phase I Cisplatin + Prexasertib Cetuximab + Prexasertib Pemetrexed Disodium + Prexasertib LY3023414 + Prexasertib Fluorouracil + Leucovorin + Prexasertib A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer Completed USA 0
NCT02168777 Phase Ib/II Refametinib + Regorafenib Refametinib Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer Terminated USA 0
NCT02202746 Phase II Lucitanib A Study to Assess the Safety and Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGF Aberrant Metastatic Breast Cancer Terminated USA 0
NCT02203513 Phase II Prexasertib A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer Completed USA 0
NCT02230319 Phase II Paclitaxel Prevention of Paclitaxel Neuropathy With Cryotherapy Unknown status USA 0
NCT02260531 Phase II Cabozantinib Trastuzumab Cabozantinib + / - Trastuzumab In Breast Cancer Patients w/ Brain Metastases Completed USA 0
NCT02265536 Phase I LY3022855 A Study of LY3022855 In Participants With Breast or Prostate Cancer Completed USA 0
NCT02303990 Phase I Pembrolizumab RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers Completed USA 0
NCT02307240 Phase I CUDC-907 Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors Completed USA 0
NCT02310464 Phase I OBI-821 + OBI-833 Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects Completed 1
NCT02314156 Phase II Telapristone Acetate Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy Unknown status USA 0
NCT02366130 Phase II Tamoxifen Denosumab + Radium Ra 223 dichloride Fulvestrant Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer Completed USA 0
NCT02379585 Phase Ib/II Cyclophosphamide + Doxorubicin + Paclitaxel Docetaxel + Pertuzumab + Trastuzumab Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Breast Cancer Terminated USA 0
NCT02384239 Phase II Fulvestrant + Palbociclib Palbociclib + Tamoxifen A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer Completed USA 0
NCT02391480 Phase I Mivebresib A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer Completed USA 0
NCT02393248 Phase Ib/II Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Recruiting USA 1
NCT02393794 Phase Ib/II Cisplatin + Nivolumab + Romidepsin Cisplatin + Romidepsin Romidepsin Plus Cisplatin in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) Suspended USA 0
NCT02414269 Phase I Cyclophosphamide + iCasp9M28z T cells iCasp9M28z T cells Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin Recruiting USA 0
NCT02540330 Phase II Fulvestrant A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant (007) Terminated USA 0
NCT02563925 Phase I Tremelimumab Brain Irradiation and Tremelimumab in Metastatic Breast Cancer Completed USA 0
NCT02564900 Phase I Trastuzumab deruxtecan Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors Active, not recruiting USA 1
NCT02576431 Phase II Larotrectinib A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) Recruiting USA | CAN 29
NCT02576665 Phase I Toca 511 + Toca FC A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) Terminated USA 0
NCT02595905 Phase II Cisplatin Cisplatin + Veliparib Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases Active, not recruiting USA 1
NCT02599363 Phase I Paclitaxel + Ribociclib A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer Active, not recruiting USA 0
NCT02605486 Phase Ib/II Bicalutamide + Palbociclib Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC) Active, not recruiting USA 0
NCT02623972 Phase II Cyclophosphamide + Doxorubicin + Eribulin A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer Active, not recruiting USA 0
NCT02639026 Phase I Durvalumab + Tremelimumab Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers Active, not recruiting USA 0
NCT02640508 Phase II Eribulin + Lenvatinib Eribulin and Lenvatinib in Advanced Solid Tumors Active, not recruiting USA 0
NCT02643303 Phase Ib/II Durvalumab + Poly ICLC Tremelimumab A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Active, not recruiting USA 0
NCT02646319 Phase I Nab-Rapamycin Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Completed USA 0
NCT02650635 Phase I Cyclophosphamide + Motolimod + Pegfilgrastim TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors Terminated USA 0
NCT02721433 FDA approved Denosumab + pamidronate + Zoledronic acid 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases (REaCT-BTA) Completed CAN 0
NCT02725489 Phase II Durvalumab + FANG vaccine Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers Completed USA 0
NCT02725541 Phase II Ado-trastuzumab emtansine Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer Withdrawn USA 0
NCT02734004 Phase Ib/II Durvalumab + Olaparib Bevacizumab + Durvalumab + Olaparib A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA) Completed USA 6
NCT02746328 Phase II Enobosarm Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass Completed USA 0
NCT02754011 Phase I Capecitabine + Ribociclib Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced/Metastatic Breast Cancer HER2 Negative (GEP14-LEECAP) Recruiting 1
NCT02784795 Phase I Cisplatin + Gemcitabine + LY3039478 Carboplatin + Gemcitabine + LY3039478 LY3023414 + LY3039478 Abemaciclib + LY3039478 LY3039478 + Taladegib LY3039478 LY3023414 A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors Completed USA 3
NCT02874430 Phase II Doxycycline + Metformin Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Active, not recruiting USA 0
NCT02900469 Phase 0 Denosumab Safety Study of Denosumab to Treat Breast Cancer Completed USA 0
NCT02926690 Phase I OTS167 Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer Recruiting USA 0
NCT02939274 Phase II Verteporfin An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne) for the Treatment of Cutaneous Metastases of Breast Cancer Unknown status USA 0
NCT02953782 Phase Ib/II Cetuximab + Hu5F9-G4 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer Completed USA 0
NCT02965885 Phase I Pimitespib A Study of TAS-116 in Patients With Solid Tumors Completed USA 2
NCT02980341 Phase Ib/II U3-1402 Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer Active, not recruiting USA 1
NCT02985658 Phase I Cisplatin Veliparib Vinorelbine Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer No longer available USA 0
NCT02999477 Phase I Pembrolizumab Nab-paclitaxel A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer Recruiting USA 0
NCT03006172 Phase I GDC-0077 + Letrozole + Palbociclib GDC-0077 Fulvestrant + GDC-0077 GDC-0077 + Letrozole To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer Recruiting USA | CAN 3
NCT03025035 Phase II Olaparib + Pembrolizumab Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated Breast Cancer Recruiting USA 0
NCT03032107 Phase I Ado-trastuzumab emtansine + Pembrolizumab A Study Of Pembrolizumab In Combination With Trastuzumab-DM1 Active, not recruiting USA 0
NCT03032406 Phase II Everolimus + Hydroxychloroquine Everolimus Hydroxychloroquine CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer Recruiting USA 0
NCT03044730 Phase II Capecitabine + Pembrolizumab Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT03066947 Phase Ib/II Cyclophosphamide + Interferon alpha-2b + SV-BR-1-GM SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer Completed USA 0
NCT03093350 Phase II MultiTAA-specific T cells TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer (TACTIC) Active, not recruiting USA 0
NCT03095352 Phase II Carboplatin + Pembrolizumab + Trastuzumab Carboplatin Carboplatin + Trastuzumab Carboplatin + Pembrolizumab Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease Recruiting USA 0
NCT03099174 Phase I Abemaciclib + Xentuzumab Abemaciclib + Letrozole + Xentuzumab Abemaciclib + Anastrozole + Xentuzumab Abemaciclib + Fulvestrant + Xentuzumab This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer. Active, not recruiting USA 6
NCT03101748 Phase Ib/II Neratinib + Paclitaxel + Pertuzumab + Trastuzumab Cyclophosphamide + Doxorubicin + Neratinib + Paclitaxel 3HT With Taxol for Metastatic Breast Cancer Recruiting USA 0
NCT03102606 Phase II Plinabulin Pegfilgrastim Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1) Completed USA 3
NCT03154281 Phase I Everolimus + Niraparib Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Ovarian and Breast Active, not recruiting USA 0
NCT03179904 Phase II Paclitaxel + Trastuzumab + TVB-2640 FASN Inhibitor TVB-2640, Paclitaxel, and Trastuzumab in Treating Patients With HER2 Positive Advanced Breast Cancer Recruiting USA 0
NCT03199586 Phase I NP-G2-044 Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) Completed USA 0
NCT03207529 Phase I Alpelisib + Enzalutamide Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer Recruiting USA 0
NCT03237572 Phase I Pembrolizumab Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer (Breast-48) Recruiting USA 0
NCT03248492 Phase II Trastuzumab deruxtecan A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1) Active, not recruiting USA | CAN 7
NCT03262935 Phase III Capecitabine + Lapatinib Trastuzumab Duocarmazine Eribulin + Trastuzumab Capecitabine + Trastuzumab Trastuzumab + Vinorelbine SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (TULIP) Active, not recruiting USA | CAN 9
NCT03272334 Phase Ib/II HER2 BATs + Pembrolizumab Her2-BATS and Pembrolizumab in Metastatic Breast Cancer (Breast-47) Recruiting USA 0
NCT03292536 Phase I Merestinib Merestinib on Bone Metastases in Subjects With Breast Cancer Terminated USA 0
NCT03317405 Phase I Z-endoxifen HCl Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery Active, not recruiting USA 0
NCT03328026 Phase Ib/II Cyclophosphamide + Interferon alpha-2b + Ipilimumab + SV-BR-1-GM Cyclophosphamide + Interferon alpha-2b + Pembrolizumab + SV-BR-1-GM Rollover Study of SV-BR-1-GM in Combination With Ipilimumab or Pembrolizumab Recruiting USA 0
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Recruiting USA 0
NCT03342417 Phase II Ipilimumab + Nivolumab Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients Terminated USA 0
NCT03344965 Phase II Olaparib Olaparib In Metastatic Breast Cancer Recruiting USA 0
NCT03363776 Phase Ib/II BMS-986277 BMS-986277 + Nivolumab An Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers Terminated USA | CAN 0
NCT03367689 Phase II Olaparib A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single Agent (NOBROLA) Recruiting 1
NCT03394027 Phase II ONC201 ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma Completed USA 0
NCT03396211 Phase I Nivolumab + Rivoceranib Study to Evaluate Apatinib Plus Nivolumab in Patients With Unresectable or Metastatic Cancer Active, not recruiting USA 0
NCT03400254 Phase Ib/II Gedatolisib + Hydroxychloroquine Hydroxychloroquine A Phase Ib/II Trial of Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER") (GLACIER) Withdrawn USA 0
NCT03409458 Phase Ib/II Avelumab + Imifoplatin A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab (PAVE-1) Recruiting USA 1
NCT03410927 Phase Ib/II TAS0728 A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities Active, not recruiting USA 3
NCT03412877 Phase II Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL + Pembrolizumab Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer Suspended USA 0
NCT03422679 Phase Ib/II CB-103 Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies Recruiting USA 3
NCT03448042 Phase I BTRC 4017A A Phase I Study of BTRC4017A in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers Recruiting USA | CAN 12
NCT03449238 Phase Ib/II Pembrolizumab Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients Recruiting USA 0
NCT03454529 Phase II Simvastatin The Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast Cancer Recruiting USA 0
NCT03476681 Phase I NEO-201 QUILT-3.017: Study of NEO-201 in Solid Tumors Recruiting USA 0
NCT03518606 Phase Ib/II Durvalumab + Tremelimumab + Vinorelbine Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours (MOVIE) Active, not recruiting 1
NCT03523572 Phase I Nivolumab + Trastuzumab deruxtecan Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer Active, not recruiting USA 6
NCT03565445 Phase I ASP1948 + Nivolumab ASP1948 A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors Recruiting USA | CAN 7
NCT03596372 Phase I BAY1834942 Study of BAY1834942 in Patients With Solid Tumors Completed USA | CAN 1
NCT03602079 Phase Ib/II A166 Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene Recruiting USA 0
NCT03608020 Phase Ib/II BMX-001 A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy Recruiting USA 0
NCT03628677 Phase I AB154 AB154 + GLS-010 A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies Recruiting USA 1
NCT03629756 Phase I AB928 + GLS-010 A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies Completed USA 1
NCT03632941 Phase II Pembrolizumab AVX901 + Pembrolizumab AVX901 A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer Recruiting USA 0
NCT03635632 Phase I C7R-GD2.CART cells Cyclophosphamide + Fludarabine C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) Recruiting USA 0
NCT03641755 Phase Ib/II Olaparib + Sapacitabine A Phase Ib/II Study of Olaparib With Sapacitabine in BRCA Mutant Breast Cancer Recruiting USA 0
NCT03661424 Phase I HER2 BATs BATs in Patients With Breast Cancer and Leptomeningeal Metastases Recruiting USA 0
NCT03674567 Phase Ib/II FLX475 + Pembrolizumab FLX475 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Recruiting USA 5
NCT03717415 Phase Ib/II Carboplatin + Rebastinib A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors Active, not recruiting USA 0
NCT03719768 Phase I Avelumab Avelumab With Radiotherapy in Patients With Leptomeningeal Disease Recruiting USA 0
NCT03734029 Phase III Trastuzumab deruxtecan Nab-paclitaxel Capecitabine Paclitaxel Gemcitabine Eribulin Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] Active, not recruiting USA | CAN 18
NCT03742245 Phase I Olaparib + Vorinostat Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer Recruiting USA 0
NCT03763604 Expanded access Abemaciclib Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer Available CAN 13
NCT03786094 Phase III Eribulin Eribulin + POL6326 Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer Active, not recruiting USA 12
NCT03789097 Phase Ib/II CDX-301 + Pembrolizumab + Poly ICLC Vaccination With Flt3L, Radiation, and Poly-ICLC Recruiting USA 0
NCT03796273 Phase I Ketoconazole Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases Recruiting USA 0
NCT03807765 Phase I Nivolumab Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases Active, not recruiting USA 0
NCT03820141 Phase II Durvalumab + Pertuzumab + Trastuzumab Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer (DTP) Recruiting USA 0
NCT03821233 Phase I ZW49 A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers Recruiting USA | CAN 2
NCT03847168 Phase I KN026 KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer Recruiting USA 0
NCT03878524 Phase I Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) Recruiting USA 0
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Completed USA 4
NCT03950570 Phase I ORIN1001 + Paclitaxel ORIN1001 ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer Recruiting USA 0
NCT03955640 Phase I Olaparib Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences Recruiting USA 0
NCT03964532 Phase Ib/II Talazoparib Avelumab + Talazoparib TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer Recruiting USA 0
NCT03970382 Phase I NeoTCR-P1 T-cells + Nivolumab NeoTCR-P1 T-cells A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors Recruiting USA 0
NCT03982004 Phase I Imiquimod + Pembrolizumab + Sargramostim Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer Terminated USA 0
NCT03995706 Phase I Sacituzumab govitecan-hziy Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0 Recruiting USA 0
NCT03997968 Phase Ib/II CYT01B A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors Recruiting USA 0
NCT04009044 Phase II Afimoxifene Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast Recruiting USA 0
NCT04020575 Phase I huMNC2-CAR44 CAR T cells Autologous huMNC2-CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*) Active, not recruiting USA 0
NCT04029922 Phase I MT-5111 Study of MT-5111 in HER2-positive Solid Tumors (MT-5111) Recruiting USA 0
NCT04115306 Phase I PMD-026 Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer Recruiting USA 0
NCT04134312 Phase I MVA-BN-Brachyury A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer Completed USA 0
NCT04134884 Phase I Decitabine and Cedazuridine + Talazoparib Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer Recruiting USA 0
NCT04143711 Phase Ib/II DF1001 DF1001 + Pembrolizumab Study of DF1001 in Patients With Advanced Solid Tumors Recruiting USA 4
NCT04143789 Phase Ib/II AP-002 Evaluation of AP-002 in Patients With Solid Tumors Unknown status USA 0
NCT04145622 Phase Ib/II DS-7300a Study of DS-7300a in Participants With Advanced Solid Malignant Tumors Recruiting USA 1
NCT04148937 Phase I LY3475070 LY3475070 + Pembrolizumab A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer Active, not recruiting USA 2
NCT04158336 Phase Ib/II ZN-c3 Talazoparib + ZN-c3 Pembrolizumab + ZN-c3 A Study of ZN-c3 in Participants With Solid Tumors Recruiting USA 0
NCT04169841 Phase II Durvalumab + Olaparib + Tremelimumab Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment (GUIDE2REPAIR) Recruiting 1
NCT04172597 Phase II Poziotinib A Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies Recruiting USA 0
NCT04222413 Phase I Metarrestin Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors Recruiting USA 0
NCT04235101 Phase I Niraparib + Trastuzumab Duocarmazine Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors Recruiting 3
NCT04244552 Phase I ATRC-101 First-in-Human Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies Recruiting USA 0
NCT04246671 Phase Ib/II TAEK-VAC-HerBy TAEK-VAC-HerBy + unspecified ERBB2 antibody + unspecified immune checkpoint inhibitor Pertuzumab + TAEK-VAC-HerBy + Trastuzumab Ado-trastuzumab emtansine + TAEK-VAC-HerBy TAEK-VAC-HerBy + Trastuzumab Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients Recruiting USA 0
NCT04250597 Phase I GNX102 Study of GNX102 in Patients With Advanced Solid Tumors Recruiting USA 1
NCT04259450 Phase Ib/II AFM24 Study to Assess AFM24 in Advanced Solid Cancers Recruiting USA 2
NCT04272801 Phase I Anastrozole Letrozole Tamoxifen Exemestane Neoadjuvant Endocrine Therapy Tolerance in Geriatric Early Stage ER+ Breast Cancer (Breast52) Recruiting USA 0
NCT04273061 Phase II Atezolizumab Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity (CAPTIV-8) Recruiting CAN 0
NCT04289805 FDA approved Letrozole Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE) (fAMHOPE) Recruiting 2
NCT04319757 Phase I ACE1702 + Cyclophosphamide + Fludarabine ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors Recruiting USA 0
NCT04367675 Phase I INO-5401 INO-5401 + INO-9012 INO 5401 Vaccination in BRCA1/2 Mutation Carriers Recruiting USA 0
NCT04389632 Phase I SGN-B6A A Study of SGN-B6A in Advanced Solid Tumors Recruiting USA 3
NCT04418219 Phase Ib/II Cyclophosphamide + Interferon alpha-2b + Pembrolizumab + SV-BR-1-GM A Breast Cancer Vaccine (SV-BR-1-GM) in Combination With Pembrolizumab for the Treatment of Persistent, Recurrent, or Metastatic Breast Cancer Withdrawn USA 0
NCT04444427 Phase Ib/II GLR2007 Evaluation of GLR2007 for Advanced Solid Tumors Recruiting USA 0
NCT04454528 Phase Ib/II Pembrolizumab BreastVax: Radiation Boost to Enhance Effectiveness of Immune Checkpoint Blockade Therapy in Operable Breast Cancer Recruiting USA 0
NCT04523857 Phase II Abemaciclib Abemaciclib + Hydroxychloroquine ABemacicliB, HydroxYchloroquine, or the Combination to Target Minimal Residual Disease in Breast Cancer (ABBY) Not yet recruiting USA 0
NCT04550494 Phase II Talazoparib Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations Recruiting USA 0
NCT04591431 Phase II Everolimus Nivolumab Itacitinib Erlotinib Ponatinib Pemigatinib Ipatasertib Ipilimumab Cobimetinib Atezolizumab Palbociclib Entrectinib Vemurafenib Lapatinib Trastuzumab Brigatinib Alectinib Ado-trastuzumab emtansine Pertuzumab Vismodegib The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME) Recruiting 1
NCT04616248 Phase I CDX-1140 + CDX-301 + Poly ICLC Radio-immunotherapy (CDX-301, Radiotherapy, CDX-1140 and Poly-ICLC) for the Treatment of Unresectable or Metastatic Breast Cancer Patients Not yet recruiting USA 0
NCT04641247 Phase II Niraparib A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study Recruiting USA | CAN 0
NCT04659603 Phase II Diphenhydramine + SAR408701 SAR408701 in Patients With CEACAM5-positive Advanced Solid Tumors (CARMEN-BT01) Recruiting 6
NCT04673448 Phase I Dostarlimab-gxly + Niraparib Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer Recruiting USA 0
NCT04695847 Phase I M1231 M1231 in Participants With Solid Tumors Recruiting USA | CAN 0
NCT04699630 Phase II U3-1402 A Study of U3-1402 in Subjects With Metastatic Breast Cancer Recruiting USA 0
NCT04704661 Phase I Ceralasertib + Trastuzumab deruxtecan Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Recruiting USA 0
NCT04714983 Phase I DNX-2440 DNX-2440 for Resectable Colorectal Liver Metastasis Recruiting USA 0
NCT04717375 Phase Ib/II BND-22 Study of BND-22 in Participants With Advanced Solid Tumors Recruiting USA 1
NCT04829604 Phase II ARX-788 ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) (ACE-Breast03) Recruiting USA 1
NCT04836195 Phase I PCLX-001 Phase I Trial of PCLX-001 in B-cell Non-Hodgkin Lymphoma and Advanced Solid Malignancies Recruiting CAN 0
NCT04890613 Phase I CX-5461 Study of CX-5461 in Patients With Solid Tumours and BRCA2 and/or PALB2 Mutation Recruiting CAN 0
NCT04957290 Phase Ib/II NOX66 A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors Recruiting USA 0
NCT05000294 Phase Ib/II Atezolizumab + Tivozanib Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types Recruiting USA 0
NCT05006794 Phase I GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies Recruiting USA 0
NCT05027139 Phase Ib/II ALX148 + ZW25 A Study of Zanidatamab (ZW25) With ALX148 in Patients With Advanced HER2-expressing Cancer Recruiting USA 0